{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:58:10Z","timestamp":1769759890371,"version":"3.49.0"},"reference-count":19,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To determine the long-term outcomes of ocular adnexal lesions in immunoglobulin G4-related ophthalmic disease (IgG4-ROD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, non-randomised exploratory study included 82 patients with ocular adnexal lesions. We evaluated the long-term outcomes in 71 patients during the median follow-up period of 30 months, who underwent either watchful waiting (n=20; range 12\u201390 months) or systemic corticosteroid treatment, delivered according to consensus guidelines (n=51; range 9\u2013 115 months). We also analysed factors that might contribute to recalcitrance to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 82 patients, 40 (49%) were male, and the median patient age was 60 years old. Twenty-one (26%) patients with extraocular muscle (EOM) and\/or trigeminal nerve branch (CN V) enlargements had a significantly high frequency of multiple ocular adnexal lesions (p&lt;0.0001, Fisher\u2019s exact test). In addition, two patients developed EOM and\/or CN V enlargements de novo over time. Twenty patients with solitary lacrimal gland enlargements preferred watchful waiting, due to mild symptoms. Of these, 18 (90%) lesions remained dormant throughout a median follow-up of 27 months. Among 51 patients treated with corticosteroids, 31 (61%) experienced relapses after treatment and required systemic low-dose maintenance treatment. A multivariate analysis indicated that EOM and\/or CN V enlargements comprised a risk factor for relapse (HR 2.7; 95% CI 1.1 to 6.7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This exploratory study showed that different types of ocular adnexal lesions in IgG4-ROD displayed distinct proliferative activities. Our results suggested that EOM and\/or CN V enlargements might be secondary lesions that confer refractoriness to systemic corticosteroid treatment recommended by consensus guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-313730","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T21:25:33Z","timestamp":1562275533000},"page":"345-349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term outcomes of ocular adnexal lesions in IgG4-related ophthalmic disease"],"prefix":"10.1136","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-0267","authenticated-orcid":false,"given":"Toshinobu","family":"Kubota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzuko","family":"Moritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"2020060209150906000_104.3.345.1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.72"},{"key":"2020060209150906000_104.3.345.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204907"},{"key":"2020060209150906000_104.3.345.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650"},{"key":"2020060209150906000_104.3.345.4","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020060209150906000_104.3.345.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311519"},{"key":"2020060209150906000_104.3.345.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.07.024"},{"key":"2020060209150906000_104.3.345.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-014-0352-2"},{"issue":"1, supplement 64","key":"2020060209150906000_104.3.345.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/412896","article-title":"Orbital IgG4-related disease: clinical features and diagnosis","volume":"2012","author":"Kubota","year":"2012","journal-title":"ISRN Rheumatol"},{"key":"2020060209150906000_104.3.345.9","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.45"},{"key":"2020060209150906000_104.3.345.10","doi-asserted-by":"crossref","unstructured":"Kubota T , Moritani S , Sakuma M . Tarsal IgG4-related disease. JAMA Ophthalmol 2015;133:e143272.doi:10.1001\/jamaophthalmol.2014.3272","DOI":"10.1001\/jamaophthalmol.2014.3272"},{"key":"2020060209150906000_104.3.345.11","doi-asserted-by":"publisher","DOI":"10.4065\/80.1.75"},{"key":"2020060209150906000_104.3.345.12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"2020060209150906000_104.3.345.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.008"},{"key":"2020060209150906000_104.3.345.14","doi-asserted-by":"crossref","unstructured":"Ebbo M , Patient M , Grados A , et al . Ophthalmic manifestations in IgG4-related disease: clinical presentation and response to treatment in a French case-series. Medicine 2017;96:e6205.doi:10.1097\/MD.0000000000006205","DOI":"10.1097\/MD.0000000000006205"},{"key":"2020060209150906000_104.3.345.15","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.16"},{"key":"2020060209150906000_104.3.345.16","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3865"},{"key":"2020060209150906000_104.3.345.17","doi-asserted-by":"crossref","unstructured":"Wolfson AR , Hamilos DL . Recent advances in understanding and managing IgG4-related disease. F1000Res 2017;6.doi:10.12688\/f1000research.9399.1","DOI":"10.12688\/f1000research.9399.1"},{"key":"2020060209150906000_104.3.345.18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00417-013-2548-4","article-title":"Location and frequency of lesions in patients with IgG4-related ophthalmic diseases","volume":"252","author":"Sogabe","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020060209150906000_104.3.345.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu228"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-313730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:59:34Z","timestamp":1601110774000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-313730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,21]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bjophthalmol-2018-313730"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313730","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]}}}